Truseltiq (infigratinib capsules – QED Therapeutics) — Cigna

Initial criteria

• Patient is currently receiving Truseltiq; AND
• Patient age ≥ 18 years; AND
• Patient has unresectable locally advanced or metastatic disease; AND
• Patient has fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an approved test; AND
• Truseltiq is used as subsequent therapy

Approval duration

1 year